Portal de Periódicos da CAPES

Cutaneous autoimmune diseases during COVID‐19 pandemic

2020; Wiley; Volume: 34; Issue: 11 Linguagem: Francês

10.1111/jdv.16753

1468-3083

Claudia Günther, Roland Aschoff, Stefan Beissert,

Inflammasome and immune disorders

Journal of the European Academy of Dermatology and VenereologyVolume 34, Issue 11 p. e667-e670 Letter to the Editor Cutaneous autoimmune diseases during COVID-19 pandemic C. Günther, Corresponding Author C. Günther [email protected] orcid.org/0000-0002-4330-1861 Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany Correspondence: C. Günther. E-mail: [email protected]Search for more papers by this authorR. Aschoff, R. Aschoff Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GermanySearch for more papers by this authorS. Beissert, S. Beissert Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GermanySearch for more papers by this author C. Günther, Corresponding Author C. Günther [email protected] orcid.org/0000-0002-4330-1861 Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, Germany Correspondence: C. Günther. E-mail: [email protected]Search for more papers by this authorR. Aschoff, R. Aschoff Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GermanySearch for more papers by this authorS. Beissert, S. Beissert Department of Dermatology, University Hospital Carl Gustav Carus, Technical University Dresden, Dresden, GermanySearch for more papers by this author First published: 13 June 2020 https://doi.org/10.1111/jdv.16753Citations: 10Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat References 1Huang C, Wang Y, Li X et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497–506. 10.1016/S0140-6736(20)30183-5 CASPubMedWeb of Science®Google Scholar 2Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med 2020; 382: e102. 10.1056/NEJMoa2007621 CASPubMedWeb of Science®Google Scholar 3Zhou F, Yu T, Du R et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–1062. 10.1016/S0140-6736(20)30566-3 CASPubMedWeb of Science®Google Scholar 4Ackermann M, Verleden SE, Kuehnel M et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med 2020. https://doi.org/10.1056/NEJMoa2015432 10.1056/NEJMoa2015432 PubMedWeb of Science®Google Scholar 5Diaz-Guimaraens B, Dominguez-Santas M, Suarez-Valle A et al. Petechial skin rash associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020. https://doi.org/10.1001/jamadermatol.2020.1741 10.1001/jamadermatol.2020.1741 PubMedWeb of Science®Google Scholar 6Joob B, Wiwanitkit V. COVID-19 can present with a rash and be mistaken for dengue. J Am Acad Dermatol 2020; 82: e177. 10.1016/j.jaad.2020.03.036 CASPubMedWeb of Science®Google Scholar 7Sanchez A, Sohier P, Benghanem S et al. Digitate papulosquamous eruption associated with severe acute respiratory syndrome coronavirus 2 infection. JAMA Dermatol 2020. https://doi.org/10.1001/jamadermatol.2020.1704 10.1001/jamadermatol.2020.1704 Web of Science®Google Scholar 8Henry D, Ackerman M, Sancelme E, Finon A, Esteve E. Urticarial eruption in COVID-19 infection. J Eur Acad Dermatol Venereol 2020; 34: e244– e245. https://doi.org/10.1111/jdv.16472 10.1111/jdv.16472 CASPubMedWeb of Science®Google Scholar 9Amatore F, Macagno N, Mailhe M et al. SARS-CoV-2 infection presenting as a febrile rash. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16528 10.1111/jdv.16528 Web of Science®Google Scholar 10van Damme C, Berlingin E, Saussez S, Accaputo O. Acute urticaria with pyrexia as the first manifestations of a COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16523 10.1111/jdv.16523 PubMedWeb of Science®Google Scholar 11Avellana Moreno R, Villa E, Avellana Moreno V, Estela Villa C, Aparicio M, Fontanella A. Cutaneous manifestation of COVID-19 in images: a case report. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16531 10.1111/jdv.16531 PubMedWeb of Science®Google Scholar 12Recalcati S. Cutaneous manifestations in COVID- 19: a first perspective. J Eur Acad Dermatol Venereol 2020; 34: e212– e213. https://doi.org/10.1111/jdv.16387 10.1111/jdv.16387 CASPubMedWeb of Science®Google Scholar 13Mahé A, Birckel E, Krieger S, Merklen C, Bottlaender L. A distinctive skin rash associated with coronavirus disease 2019? J Eur Acad Dermatol Venereol 2020; 34: e246– e247. https://doi.org/10.1111/jdv.16471 10.1111/jdv.16471 CASPubMedWeb of Science®Google Scholar 14Ehsani AH, Nasimi M, Bigdelo Z. Pityriasis rosea as a cutaneous manifestation of COVID-19 infection. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16579 10.1111/jdv.16579 PubMedWeb of Science®Google Scholar 15Jones VG, Mills M, Suarez D et al. COVID-19 and Kawasaki disease: novel virus and novel case. Hospital Pediatrics 2020; 10: 537–540. 10.1542/hpeds.2020-0123 PubMedGoogle Scholar 16Viner RM, Whittaker E. Kawasaki-like disease: emerging complication during the COVID-19 pandemic. Lancet 2020; 395: 1741–1743. 10.1016/S0140-6736(20)31129-6 CASPubMedWeb of Science®Google Scholar 17Landa N, Mendieta-Eckert M, Fonda-Pascual P, Aguirre T. Chilblain-like lesions on feet and hands during the COVID-19 Pandemic. Int J Dermatol 2020; 59: 739–743. 10.1111/ijd.14937 CASPubMedWeb of Science®Google Scholar 18Kolivras A, Dehavay F, Delplace D et al. Coronavirus (COVID-19) infection-induced chilblains: a case report with histopathologic findings. JAAD Case Rep 2020; 6: 489–492. 10.1016/j.jdcr.2020.04.011 PubMedGoogle Scholar 19Piccolo V, Neri I, Filippeschi C et al. Chilblain-like lesions during COVID-19 epidemic: a preliminary study on 63 patients. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16526 10.1111/jdv.16526 Web of Science®Google Scholar 20Recalcati S, Barbagallo T, Frasin LA et al. Acral cutaneous lesions in the time of COVID-19. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16533 10.1111/jdv.16533 Web of Science®Google Scholar 21Bouaziz J, Duong T, Jachiet M et al. Vascular skin symptoms in COVID- 19: a French observational study. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16544 10.1111/jdv.16544 Web of Science®Google Scholar 22Lyons-Weiler J. Pathogenic priming likely contributes to serious and critical illness and mortality in COVID-19 via autoimmunity. J Transl Autoimmun 2020; 3: 100051. 10.1016/j.jtauto.2020.100051 PubMedGoogle Scholar 23Kavanagh D, McGlasson S, Jury A et al. Type I interferon causes thrombotic microangiopathy by a dose-dependent toxic effect on the microvasculature. Blood 2016; 128: 2824–2833. 10.1182/blood-2016-05-715987 CASPubMedWeb of Science®Google Scholar 24Zimmermann N, Wolf C, Schwenke R et al. Assessment of clinical response to janus kinase inhibition in patients with familial chilblain lupus and TREX1 mutation. JAMA Dermatol 2019; 155(3): 342–346. https://doi.org/10.1001/jamadermatol.2018.5077 10.1001/jamadermatol.2018.5077 PubMedWeb of Science®Google Scholar 25Gunther C, Berndt N, Wolf C, Lee-Kirsch MA. Familial chilblain lupus due to a novel mutation in the exonuclease III domain of 3' repair exonuclease 1 (TREX1). JAMA Dermatol 2015; 151: 426–431. 10.1001/jamadermatol.2014.3438 PubMedWeb of Science®Google Scholar 26Lee-Kirsch MA. The type I interferonopathies. Annu Rev Med 2017; 68: 297–315. 10.1146/annurev-med-050715-104506 CASPubMedWeb of Science®Google Scholar 27Fernandez-Nieto D, Jimenez-Cauhe J, Suarez-Valle A et al. Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak. J Am Acad Dermatol 2020; 83(1): e61– e63. https://doi.org/10.1016/j.jaad.2020.04.093 10.1016/j.jaad.2020.04.093 CASPubMedWeb of Science®Google Scholar 28Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–668. 10.1136/annrheumdis-2020-217424 CASPubMedWeb of Science®Google Scholar 29Favalli EG, Agape E, Caporali R. Incidence and clinical course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 2020; 47. https://doi.org/10.3899/jrheum.200507 PubMedWeb of Science®Google Scholar 30D'Antiga L. Coronaviruses and immunosuppressed patients: the facts during the third epidemic. Liver Transplant 2020; 26: 832–834. 10.1002/lt.25756 PubMedWeb of Science®Google Scholar 31Mathian A, Mahevas M, Rohmer J et al. Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2019; 79: 837–839. Web of Science®Google Scholar 32Bozzalla Cassione E, Zanframundo G, Biglia A, Codullo V, Montecucco C, Cavagna L. COVID-19 infection in a northern-Italian cohort of systemic lupus erythematosus assessed by telemedicine. Ann Rheum Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217717 10.1136/annrheumdis-2020-217717 Web of Science®Google Scholar 33Au K, Reed G, Curtis JR et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis 2011; 70: 785–791. 10.1136/ard.2010.128637 PubMedWeb of Science®Google Scholar 34Shakshouk H, Daneshpazhooh M, Murrell DF, Lehman JS. Treatment considerations for patients with pemphigus during the COVID-19 pandemic. J Am Acad Dermatol 2020; 82: e235–e236. 10.1016/j.jaad.2020.04.005 CASPubMedWeb of Science®Google Scholar 35Kasperkiewicz M, Schmidt E, Fairley JA et al. Expert recommendations for the management of autoimmune bullous diseases during the COVID-19 pandemic. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16525 10.1111/jdv.16525 PubMedWeb of Science®Google Scholar 36Misra DP, Agarwal V, Gasparyan AY, Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol 2020; 39: 2055–2062. 10.1007/s10067-020-05073-9 PubMedWeb of Science®Google Scholar 37Gianfrancesco MA, Hyrich KL, Gossec L et al. Rheumatic disease and COVID-19: initial data from the COVID-19 Global Rheumatology Alliance provider registries. Lancet Rheumatol 2020; 2: e250– e253. 10.1016/S2665-9913(20)30095-3 PubMedGoogle Scholar 38Mihai C, Dobrota R, Schröder M et al. COVID-19 in a patient with systemic sclerosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis 2020; 79: 668–669. 10.1136/annrheumdis-2020-217442 CASPubMedWeb of Science®Google Scholar 39Guilpain P, Le Bihan C, Foulongne V et al. Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia. Ann Rheum Dis 2020. https://doi.org/10.1136/annrheumdis-2020-217549 10.1136/annrheumdis-2020-217549 Web of Science®Google Scholar 40Mathian A, Mahevas M, Rohmer J et al. Clinical Course of Coronavirus Disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 2020; 79: 837–839. 10.1136/annrheumdis-2020-217566 CASPubMedWeb of Science®Google Scholar 41Monti S, Balduzzi S, Delvino P, Bellis E, Quadrelli VS, Montecucco C. Clinical Course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; 79: 667–668. 10.1136/annrheumdis-2020-217424 CASPubMedWeb of Science®Google Scholar 42Favalli EG, Agape E, Caporali R. Incidence and Clinical Course of COVID-19 in patients with connective tissue diseases: a descriptive observational analysis. J Rheumatol 2020; 47. https://doi.org/10.3899/jrheum.200507 PubMedWeb of Science®Google Scholar 43Haberman R, Axelrad J, Chen A et al. Covid-19 in immune-mediated inflammatory diseases – case series from New York. N Engl J Med 2020. https://doi.org/10.1056/NEJMc2009567 10.1056/NEJMc2009567 PubMedWeb of Science®Google Scholar 44Balestri R, Rech G, Girardelli CR. Occurrence of SARS-CoV-2 during mycophenolate mofetil treatment for pemphigus. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16578 10.1111/jdv.16578 Web of Science®Google Scholar 45Balestri R, Rech G, Girardelli CR. SARS-CoV-2 infection in a psoriatic patient treated with IL-17 inhibitor. J Eur Acad Dermatol Venereol 2020. https://doi.org/10.1111/jdv.16571 10.1111/jdv.16571 Web of Science®Google Scholar 46Messina F, Piaserico S. SARS-CoV-2 infection in a psoriatic patient treated with IL-23 inhibitor. J Eur Acad Dermatol Venereol 2020; 34: e254– e255. https://doi.org/10.1111/jdv.16468 10.1111/jdv.16468 CASPubMedWeb of Science®Google Scholar Citing Literature Volume34, Issue11November 2020Pages e667-e670 This article also appears in:JEADV COVID-19 articles ReferencesRelatedInformation